HomeComparePKBOW vs VIG

PKBOW vs VIG: Dividend Comparison 2026

PKBOW yields 20202.02% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBOW wins by $57988137149625106432.00M in total portfolio value
10 years
PKBOW
PKBOW
● Live price
20202.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57988137149625106432.00M
Annual income
$57,428,928,743,751,610,000,000,000.00
Full PKBOW calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — PKBOW vs VIG

📍 PKBOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOWVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBOW + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PKBOW pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBOW
Annual income on $10K today (after 15% tax)
$1,717,171.72/yr
After 10yr DRIP, annual income (after tax)
$48,814,589,432,188,870,000,000,000.00/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, PKBOW beats the other by $48,814,589,432,188,870,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBOW + VIG for your $10,000?

PKBOW: 50%VIG: 50%
100% VIG50/50100% PKBOW
Portfolio after 10yr
$28994068574812553216.00M
Annual income
$28,714,464,371,875,805,000,000,000.00/yr
Blended yield
99.04%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBOW buys
0
VIG buys
0
No recent congressional trades found for PKBOW or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOWVIG
Forward yield20202.02%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$57988137149625106432.00M$32.3K
Annual income after 10y$57,428,928,743,751,610,000,000,000.00$175.21
Total dividends collected$57951242634511319040.00M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PKBOW vs VIG ($10,000, DRIP)

YearPKBOW PortfolioPKBOW Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$2,030,902$2,020,202.02$11,301$160.59+$2.02MPKBOW
2$385,615,342$383,442,277.01$12,752$162.91+$385.60MPKBOW
3$68,455,310,249$68,042,701,832.74$14,370$165.02+$68455.30MPKBOW
4$11,362,120,801,776$11,288,873,619,809.51$16,176$166.93+$11362120.79MPKBOW
5$1,763,290,309,334,738$1,751,132,840,076,837.00$18,188$168.67+$1763290309.32MPKBOW
6$255,866,846,080,109,380$253,980,125,449,121,180.00$20,432$170.25+$255866846080.09MPKBOW
7$34,717,188,276,404,167,000$34,443,410,751,098,450,000.00$22,933$171.68+$34717188276404.14MPKBOW
8$4,404,848,409,251,598,600,000$4,367,701,017,795,846,700,000.00$25,720$172.98+$4404848409251598.50MPKBOW
9$522,624,678,386,435,660,000,000$517,911,490,588,536,450,000,000.00$28,827$174.15+$522624678386435648.00MPKBOW
10$57,988,137,149,625,104,000,000,000$57,428,928,743,751,610,000,000,000.00$32,288$175.21+$57988137149625106432.00MPKBOW

PKBOW vs VIG: Complete Analysis 2026

PKBOWStock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBOW Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this PKBOW vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBOW vs SCHDPKBOW vs JEPIPKBOW vs OPKBOW vs KOPKBOW vs MAINPKBOW vs DGROPKBOW vs NOBLPKBOW vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.